IQV — IQVIA Holdings Inc.

IQVIA Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $4.1 billion, up 5.2% year-over-year (4.5% excluding COVID-related work).
• Adjusted EBITDA: $949 million, a 1.1% increase year-over-year.
• Adjusted Diluted EPS: $3.00, up 5.6% year-over-year.
• Free Cash Flow: Record high of $772 million, reflecting strong cash management.
• Net Bookings: $2.6 billion, with a book-to-bill ratio of 1.15x, indicating improved customer demand.
• Backlog: Reached $32.4 billion, a 4.1% year-over-year increase.

2. Strategic Updates and Business Highlights

• Clinical Solutions: Strong performance with net bookings up 13% year-over-year and improving client decision-making timelines.
• Technology & Analytics Solutions (TAS): Revenue grew 5% year-over-year, driven by ongoing drug launches and a strong commercial portfolio.
• Acquisitions: Continued focus on inorganic growth, including a notable acquisition in oncology (NEXT Oncology).
• AI Integration: Development of 90 AI agents across 25 use cases, aimed at enhancing operational efficiency and client offerings.
• Commercial Outsourcing: Increased demand from large pharma clients for outsourcing commercial operations, indicating a strategic shift in client needs.

3. Forward Guidance and Outlook

• Full Year 2025 Guidance: Revenue expected between $16.15 billion and $16.25 billion (4.8% to 5.5% growth). Adjusted EBITDA guidance is between $3.775 billion and $3.8 billion (2.5% to 3.1% growth). Adjusted diluted EPS projected between $11.85 and $11.95 (up 6.5% to 7.4%).
• Q4 2025 Expectations: Revenue anticipated between $4.204 billion and $4.304 billion (6.2% to 8.7% growth), with adjusted EBITDA between $1.033 billion and $1.058 billion.

4. Bad News, Challenges, or Points of Concern

• COVID-Related Revenue Decline: Continued step-down in COVID-related work impacting revenue growth.
• Market Uncertainty: While the environment is improving, there are lingering uncertainties that could affect future bookings and client decisions.
• Competitive Pricing Pressures: Although pricing has stabilized, there were earlier pressures that required alignment with market discounts, which could affect margins.
• Cancellations: Although cancellations have returned to normal levels, previous high levels during the past year due to reprioritization by large pharma could pose risks if similar trends recur.

5. Notable Q&A Insights

• "See More, Win More" Strategy: This strategy has improved RFP flows and win rates, with a focus on previously untapped markets. Management indicated that pricing pressures are less of a concern now.
• Differences in Pharma vs. Biotech: Large pharma has completed internal reprioritization, leading to stronger RFP flows, while biotech funding is improving, benefiting overall growth.
• TAS Growth Drivers: Real-world evidence and consulting services are showing positive trends, with consulting recovering from previous declines.
• AI's Role: AI is being increasingly integrated into both internal processes and client solutions, expected to enhance efficiency and potentially improve margins in the long term.

Overall, IQVIA reported strong financial results with positive momentum in bookings and strategic initiatives, while also navigating challenges related to market dynamics and previous COVID-related impacts.